Novo Nordisk and Eli Lilly ramped up lobbying efforts when US legislators targeted insulin prices
When legislators began seriously thinking about insulin prices in the US, Novo Nordisk and Eli Lilly responded by increasing their lobbying contributions.
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
In 2021, when work began on legislation pertaining to the insulin prices in the US, Novo Nordisk and US-based Eli Lilly intensified their lobbying efforts, as reported by media Stat.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Joe Biden hopes to end "outrageous" insulin prices
For subscribers
